Almac Group
https://www.almacgroup.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Almac Group
Deal Watch: Biogen, AbCellera Team To Find Novel Way To Cross Blood-Brain Barrier
Plus deals involving BiomX/Adapative Phage, One/NEX-I, Shionogi/FunPep, Taiho/Haihe, Kinnate/Pierre Fabre, StemCell Technologies/SQZ and more, as well as tech transfer agreements.
Targeting Solid Cancers With CAR-T: Japan’s Noile-Immune Looks To Partner Platform
Setting a strategic focus on solid cancers with its enhanced PRIME CAR-T technology, Koji Tamada, CEO of Noile-Immune, shared the Japanese bioventure's collaboration strategies and views on the next generation of cell therapies.
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Finance Watch: Kriya Adds $150m-Plus To Series C As It Gets Closer To The Clinic
Private Company Edition: Kriya raised the first $270m of its now $430m-plus series C venture capital round in May 2022 and has raised more than $600m to date. Also, Nexo launched with $60m in series A cash, Ossium brought in $52m in series A financing and cell therapy CDMO Kincell launched with $36m.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Services
- Contract Manufacturing Organization
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Technologies
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Almac Diagnostic Services
- Almac Discovery
- Galen Limited BioClin Laboratories Arran Chemical Company
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice